{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T12:13:48Z","timestamp":1791288828777,"version":"4.3.0"},"reference-count":134,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T00:00:00Z","timestamp":1774569600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T00:00:00Z","timestamp":1774569600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Inflammopharmacol"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1007\/s10787-026-02176-8","type":"journal-article","created":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T14:05:09Z","timestamp":1774620309000},"page":"3179-3192","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Astrocytic dysfunction in Parkinson\u2019s disease pathogenesis: focusing on alpha-synuclein"],"prefix":"10.1007","volume":"34","author":[{"given":"Zainah","family":"Al-Qahtani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hayder M.","family":"Al-kuraishy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali I.","family":"Al-Gareeb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali K.","family":"Albuhadily","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed M.","family":"Abdelaziz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mubarak","family":"Alruwaili","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaber","family":"El-Saber Batiha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,27]]},"reference":[{"key":"2176_CR1","doi-asserted-by":"publisher","first-page":"2743","DOI":"10.1007\/s10571-023-01350-8","volume":"43","author":"HM Al-kuraishy","year":"2023","unstructured":"Al-kuraishy HM, Al-Gareeb AI, Elewa YHA, Zahran MH, Alexiou A, Papadakis M, Batiha GES (2023) Parkinson\u2019s disease risk and hyperhomocysteinemia: the possible link. Cell Mol Neurobiol 43:2743\u20132759. https:\/\/doi.org\/10.1007\/s10571-023-01350-8","journal-title":"Cell Mol Neurobiol"},{"key":"2176_CR2","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1016\/j.parkreldis.2021.07.032","volume":"89","author":"DJ van Wamelen","year":"2021","unstructured":"van Wamelen DJ, Sringean J, Trivedi D, Carroll CB, Schrag AE, Odin P, Antonini A, Bloem BR, Bhidayasiri R, Chaudhuri KR (2021) Digital health technology for non-motor symptoms in people with Parkinson\u2019s disease: futile or future?. Parkinsonism Relat Disord 89:186\u2013194. https:\/\/doi.org\/10.1016\/j.parkreldis.2021.07.032","journal-title":"Parkinsonism Relat Disord"},{"key":"2176_CR3","doi-asserted-by":"publisher","DOI":"10.1016\/j.arr.2023.102075","author":"HM Al-kuraishy","year":"2023","unstructured":"Al-kuraishy HM, Jabir MS, Al-Gareeb AI, Albuhadily AK (2023) The conceivable role of prolactin hormone in Parkinson disease: the same goal but with different ways. Ageing Res Rev. https:\/\/doi.org\/10.1016\/j.arr.2023.102075","journal-title":"Ageing Res Rev"},{"key":"2176_CR4","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1007\/s00415-003-1303-x","volume":"250","author":"T Iwatsubo","year":"2003","unstructured":"Iwatsubo T (2003) Aggregation of \u03b1-synuclein in the pathogenesis of Parkinson\u2019s disease. J Neurol Supplement 250:11\u201314. https:\/\/doi.org\/10.1007\/s00415-003-1303-x","journal-title":"J Neurol Supplement"},{"key":"2176_CR5","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuint.2024.105760","author":"S Negi","year":"2024","unstructured":"Negi S, Khurana N, Duggal N (2024) The misfolding mystery: \u03b1-syn and the pathogenesis of Parkinson\u2019s disease. Neurochem Int. https:\/\/doi.org\/10.1016\/j.neuint.2024.105760","journal-title":"Neurochem Int"},{"key":"2176_CR6","doi-asserted-by":"publisher","first-page":"4971","DOI":"10.1073\/PNAS.1913904117;WGROUP:STRING:PUBLICATION","volume":"117","author":"AL Mahul-Mellier","year":"2020","unstructured":"Mahul-Mellier AL, Burtscher J, Maharjan N, Weerens L, Croisier M, Kuttler F, Leleu M, Knott GW, Lashuel HA (2020) The process of Lewy body formation, rather than simply \u03b1-synuclein fibrillization, is one of the major drivers of neurodegeneration. Proc Natl Acad Sci U S A 117:4971\u20134982. https:\/\/doi.org\/10.1073\/PNAS.1913904117;WGROUP:STRING:PUBLICATION","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2176_CR7","doi-asserted-by":"publisher","first-page":"S3","DOI":"10.3233\/JPD-181474","volume":"8","author":"ER Dorsey","year":"2018","unstructured":"Dorsey ER, Sherer T, Okun MS, Bloemd BR (2018) The emerging evidence of the Parkinson pandemic. J Parkinsons Dis 8:S3\u2013S8. https:\/\/doi.org\/10.3233\/JPD-181474","journal-title":"J Parkinsons Dis"},{"key":"2176_CR8","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.4103\/1673-5374.300980","volume":"16","author":"J Dorszewska","year":"2021","unstructured":"Dorszewska J, Kowalska M, Prendecki M, Piekut T, Koz\u0142owska J, Kozubski W (2021) Oxidative stress factors in Parkinson\u2019s disease. Neural Regen Res 16:1383\u20131391","journal-title":"Neural Regen Res"},{"key":"2176_CR9","doi-asserted-by":"publisher","first-page":"964","DOI":"10.1093\/brain\/awab446","volume":"145","author":"S Smajic","year":"2022","unstructured":"Smajic S, Prada-Medina CA, Landoulsi Z, Ghelfi J, Delcambre S, Dietrich C, Jarazo J, Henck J, Balachandran S, Pachchek S, Morris CM, Antony P, Timmermann B, Sauer S, Pereira SL, Schwamborn JC, May P, Grunewald A, Spielmann M (2022) Single-cell sequencing of human midbrain reveals glial activation and a Parkinson-specific neuronal state. Brain 145:964\u2013978. https:\/\/doi.org\/10.1093\/brain\/awab446","journal-title":"Brain"},{"key":"2176_CR10","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1007\/s10787-023-01400-z","volume":"32","author":"HM Al-kuraishy","year":"2024","unstructured":"Al-kuraishy HM, Fahad EH, Al-Windy S, El-Sherbeni SA, Negm WA, Batiha GES (2024) The effects of cholesterol and statins on Parkinson\u2019s neuropathology: a narrative review. Inflammopharmacology 32:917\u2013925. https:\/\/doi.org\/10.1007\/s10787-023-01400-z","journal-title":"Inflammopharmacology"},{"key":"2176_CR11","doi-asserted-by":"publisher","DOI":"10.1016\/j.arr.2024.102200","author":"HM Al-kuraishy","year":"2024","unstructured":"Al-kuraishy HM, Al-Hamash SM, Jabir MS, Al-Gareeb AI, Albuhadily AK, Albukhaty S, Sulaiman GM (2024) The classical and non-classical axes of renin-angiotensin system in Parkinson disease: the bright and dark side of the moon. Ageing Res Rev. https:\/\/doi.org\/10.1016\/j.arr.2024.102200","journal-title":"Ageing Res Rev"},{"key":"2176_CR12","doi-asserted-by":"publisher","first-page":"e14521","DOI":"10.1111\/cns.14521","volume":"30","author":"HM Al-kuraishy","year":"2024","unstructured":"Al-kuraishy HM, Al-Gareeb AI, Albuhadily AK, Elewa YHA, AL-Farga A, Aqlan F, Zahran MH, Batiha GES (2024) Sleep disorders cause Parkinson\u2019s disease or the reverse is true: Good GABA good night. CNS Neurosci Ther 30:e14521. https:\/\/doi.org\/10.1111\/cns.14521","journal-title":"CNS Neurosci Ther"},{"key":"2176_CR13","doi-asserted-by":"publisher","first-page":"776847","DOI":"10.3389\/fpubh.2021.776847","volume":"9","author":"Z Ou","year":"2021","unstructured":"Ou Z, Pan J, Tang S, Duan D, Yu D, Nong H, Wang Z (2021) Global trends in the incidence, prevalence, and years lived with disability of Parkinson\u2019s disease in 204 countries\/territories from 1990 to 2019. Front Public Health 9:776847. https:\/\/doi.org\/10.3389\/fpubh.2021.776847","journal-title":"Front Public Health"},{"key":"2176_CR14","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1038\/s41531-018-0058-0","volume":"4","author":"C Marras","year":"2018","unstructured":"Marras C, Beck JC, Bower JH, Roberts E, Ritz B, Ross GW, Abbott RD, Savica R, Van Den Eeden SK, Willis AW, Tanner C (2018) Prevalence of Parkinson\u2019s disease across North America. NPJ Parkinsons Dis 4:21. https:\/\/doi.org\/10.1038\/s41531-018-0058-0","journal-title":"NPJ Parkinsons Dis"},{"key":"2176_CR15","doi-asserted-by":"publisher","first-page":"170","DOI":"10.3390\/antiox11010170","volume":"11","author":"S Takahashi","year":"2022","unstructured":"Takahashi S, Mashima K (2022) Neuroprotection and disease modification by astrocytes and microglia in Parkinson disease. Antioxidants 11:170. https:\/\/doi.org\/10.3390\/antiox11010170","journal-title":"Antioxidants"},{"key":"2176_CR16","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1038\/s41583-022-00641-1","volume":"24","author":"AN Brandebura","year":"2023","unstructured":"Brandebura AN, Paumier A, Onur TS, Allen NJ (2023) Astrocyte contribution to dysfunction, risk and progression in neurodegenerative disorders. Nat Rev Neurosci 24:23\u201339. https:\/\/doi.org\/10.1038\/s41583-022-00641-1","journal-title":"Nat Rev Neurosci"},{"key":"2176_CR17","doi-asserted-by":"publisher","first-page":"115154","DOI":"10.1016\/j.chaos.2024.115154","volume":"185","author":"Z Cao","year":"2024","unstructured":"Cao Z, Du L, Zhang H, Shen Z, Deng Z (2024) Double-edged effect of astrocyte in the transition of physiopathological states in Parkinson\u2019s disease. Chaos Solitons Fractals 185:115154. https:\/\/doi.org\/10.1016\/j.chaos.2024.115154","journal-title":"Chaos Solitons Fractals"},{"key":"2176_CR18","doi-asserted-by":"publisher","first-page":"668517","DOI":"10.3389\/fendo.2021.668517","volume":"12","author":"P Mulica","year":"2021","unstructured":"Mulica P, Gr\u00fcnewald A, Pereira SL (2021) Astrocyte-neuron metabolic crosstalk in neurodegeneration: a mitochondrial perspective. Front Endocrinol (Lausanne) 12:668517. https:\/\/doi.org\/10.3389\/fendo.2021.668517","journal-title":"Front Endocrinol (Lausanne)"},{"key":"2176_CR19","doi-asserted-by":"publisher","first-page":"109102","DOI":"10.1016\/j.exer.2022.109102","volume":"220","author":"AN Strat","year":"2022","unstructured":"Strat AN, Kirschner A, Yoo H, Singh A, Bagu\u00e9 T, Li H, Herberg S, Ganapathy PS (2022) Engineering a 3D hydrogel system to study optic nerve head astrocyte morphology and behavior. Exp Eye Res 220:109102. https:\/\/doi.org\/10.1016\/j.exer.2022.109102","journal-title":"Exp Eye Res"},{"key":"2176_CR20","doi-asserted-by":"publisher","first-page":"780","DOI":"10.4149\/BLL_2024_119","volume":"125","author":"I Sivakova","year":"2024","unstructured":"Sivakova I, Polak S, Perzelova A (2024) Problematic visualization of human protoplasmic astrocytes Immunohistochemical stains. Bratisl Lek Listy 125:780\u2013784. https:\/\/doi.org\/10.4149\/BLL_2024_119","journal-title":"Bratisl Lek Listy"},{"key":"2176_CR21","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/s11064-019-02926-x","volume":"46","author":"S K\u00f6hler","year":"2021","unstructured":"K\u00f6hler S, Winkler U, Hirrlinger J (2021) Heterogeneity of astrocytes in grey and white matter. Neurochem Res 46:3\u201314. https:\/\/doi.org\/10.1007\/s11064-019-02926-x","journal-title":"Neurochem Res"},{"key":"2176_CR22","doi-asserted-by":"publisher","first-page":"732","DOI":"10.3390\/metabo11110732","volume":"11","author":"CDB Murat","year":"2021","unstructured":"Murat CDB, Garc\u00eda-C\u00e1ceres C (2021) Astrocyte gliotransmission in the regulation of systemic metabolism. Metabolites 11:732. https:\/\/doi.org\/10.3390\/metabo11110732","journal-title":"Metabolites"},{"key":"2176_CR23","doi-asserted-by":"publisher","first-page":"102331","DOI":"10.1016\/j.pneurobio.2022.102331","volume":"217","author":"JV Andersen","year":"2022","unstructured":"Andersen JV, Schousboe A, Verkhratsky A (2022) Astrocyte energy and neurotransmitter metabolism in Alzheimer\u2019s disease: Integration of the glutamate\/GABA-glutamine cycle. Prog Neurobiol 217:102331. https:\/\/doi.org\/10.1016\/j.pneurobio.2022.102331","journal-title":"Prog Neurobiol"},{"key":"2176_CR24","doi-asserted-by":"publisher","DOI":"10.3389\/fncel.2022.1037641","author":"AO Cuellar-Santoyo","year":"2023","unstructured":"Cuellar-Santoyo AO, Ruiz-Rodr\u00edguez VM, Mares-Barbosa TB, Patr\u00f3n-Soberano A, Howe AG, Portales-P\u00e9rez DP, Miquelaj\u00e1uregui A, Graf AM (2023) Estrada-S\u00e1nchez, Revealing the contribution of astrocytes to glutamatergic neuronal transmission. Front Cell Neurosci. https:\/\/doi.org\/10.3389\/fncel.2022.1037641","journal-title":"Front Cell Neurosci"},{"key":"2176_CR25","doi-asserted-by":"publisher","first-page":"665334","DOI":"10.3389\/fneur.2021.665334","volume":"12","author":"MRS Sandhu","year":"2021","unstructured":"Sandhu MRS, Gruenbaum BF, Gruenbaum SE, Dhaher R, Deshpande K, Funaro MC, Lee TSW, Zaveri HP, Eid T (2021) Astroglial Glutamine Synthetase and the Pathogenesis of Mesial Temporal Lobe Epilepsy. Front Neurol 12:665334. https:\/\/doi.org\/10.3389\/fneur.2021.665334","journal-title":"Front Neurol"},{"key":"2176_CR26","doi-asserted-by":"publisher","first-page":"150","DOI":"10.3390\/cells13020150","volume":"13","author":"G Schiera","year":"2024","unstructured":"Schiera G, Di Liegro CM, Schir\u00f2 G, Sorbello G, Di Liegro I (2024) Involvement of Astrocytes in the formation, maintenance, and function of the blood\u2013brain barrier. Cells 13:150. https:\/\/doi.org\/10.3390\/cells13020150","journal-title":"Cells"},{"key":"2176_CR27","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1007\/s00422-024-00994-z","volume":"118","author":"DW Garcia","year":"2024","unstructured":"Garcia DW, Jacquir S (2024) Astrocyte-mediated neuronal irregularities and dynamics: the complexity of the tripartite synapse. Biol Cybern 118:249\u2013266. https:\/\/doi.org\/10.1007\/s00422-024-00994-z","journal-title":"Biol Cybern"},{"key":"2176_CR28","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1042\/EBC20220075","volume":"67","author":"A Almeida","year":"2023","unstructured":"Almeida A, Jimenez-Blasco D, Bola\u00f1os JP (2023) Cross-talk between energy and redox metabolism in astrocyte-neuron functional cooperation. Essays Biochem 67:17\u201326. https:\/\/doi.org\/10.1042\/EBC20220075","journal-title":"Essays Biochem"},{"key":"2176_CR29","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.neures.2023.02.001","volume":"197","author":"M Albini","year":"2023","unstructured":"Albini M, Krawczun-Rygmaczewska A, Cesca F (2023) Astrocytes and brain-derived neurotrophic factor (BDNF). Neurosci Res 197:42\u201351","journal-title":"Neurosci Res"},{"key":"2176_CR30","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1007\/s11064-022-03773-z","volume":"48","author":"L Henning","year":"2023","unstructured":"Henning L, Unichenko P, Bedner P, Steinh\u00e4user C, Henneberger C (2023) Overview Article Astrocytes as Initiators of Epilepsy. Neurochem Res 48:1091\u20131099. https:\/\/doi.org\/10.1007\/s11064-022-03773-z","journal-title":"Neurochem Res"},{"key":"2176_CR31","doi-asserted-by":"publisher","first-page":"814285","DOI":"10.3389\/fphys.2022.814285","volume":"13","author":"S Wang","year":"2022","unstructured":"Wang S, Wang B, Shang D, Zhang K, Yan X, Zhang X (2022) Ion channel dysfunction in astrocytes in neurodegenerative diseases. Front Physiol 13:814285. https:\/\/doi.org\/10.3389\/fphys.2022.814285","journal-title":"Front Physiol"},{"key":"2176_CR32","doi-asserted-by":"publisher","first-page":"662017","DOI":"10.3389\/fendo.2021.662017","volume":"12","author":"O Barca-Mayo","year":"2021","unstructured":"Barca-Mayo O, L\u00f3pez M, Clocks A, Homeostasis G (2021) Front Endocrinol (Lausanne) 12:662017. https:\/\/doi.org\/10.3389\/fendo.2021.662017","journal-title":"Front Endocrinol (Lausanne)"},{"key":"2176_CR33","doi-asserted-by":"publisher","DOI":"10.1021\/acsptsci.4c00614","author":"S Al-Jaf","year":"2025","unstructured":"Al-Jaf S, Soliman AY, El-Yazbi AF, Abd-Elrahman KS (2025) Unveiling the interplay: neurovascular coupling, astrocytes and G protein-coupled receptors in alzheimer\u2019s disease. ACS Pharmacol Transl Sci. https:\/\/doi.org\/10.1021\/acsptsci.4c00614","journal-title":"ACS Pharmacol Transl Sci"},{"key":"2176_CR34","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1111\/jnc.15941","volume":"167","author":"MB Cieri","year":"2023","unstructured":"Cieri MB, Villarreal A, Gomez-Cuautle DD, Mailing I, Ramos AJ (2023) Progression of reactive gliosis and astroglial phenotypic changes following stab wound-induced traumatic brain injury in mice. J Neurochem 167:183\u2013203. https:\/\/doi.org\/10.1111\/jnc.15941","journal-title":"J Neurochem"},{"key":"2176_CR35","doi-asserted-by":"publisher","first-page":"105080","DOI":"10.1016\/j.neuint.2021.105080","volume":"148","author":"YY Fan","year":"2021","unstructured":"Fan YY, Huo J (2021) A1\/A2 astrocytes in central nervous system injuries and diseases: angels or devils? Neurochem Int 148:105080. https:\/\/doi.org\/10.1016\/j.neuint.2021.105080","journal-title":"Neurochem Int"},{"key":"2176_CR36","doi-asserted-by":"publisher","first-page":"13707","DOI":"10.3390\/ijms241813707","volume":"24","author":"M Za\u0142uski","year":"2023","unstructured":"Za\u0142uski M, \u0141a\u017cewska D, Ja\u015bko P, Honkisz-Orzechowska E, Kuder KJ, Brockmann A, Latacz G, Zygmunt M, Kaleta M, Greser BA, Olejarz-Maciej A, Jastrz\u0119bska-Wi\u0119sek M, Vielmuth C, M\u00fcller CE (2023) Kie\u0107-Kononowicz, anti-inflammatory activities of 8-benzylaminoxanthines showing high adenosine A2A and dual A1\/A2A receptor affinity. Int J Mol Sci 24:13707. https:\/\/doi.org\/10.3390\/ijms241813707","journal-title":"Int J Mol Sci"},{"key":"2176_CR37","doi-asserted-by":"publisher","first-page":"20241041","DOI":"10.1515\/med-2024-1041","volume":"19","author":"L Shao","year":"2024","unstructured":"Shao L, Wang C, Xu G, Tu Z, Yu X, Weng C, Liu J, Jian Z (2024) Utilizing reactive oxygen species-scavenging nanoparticles for targeting oxidative stress in the treatment of ischemic stroke: A review. Open Med (Poland) 19:20241041. https:\/\/doi.org\/10.1515\/med-2024-1041","journal-title":"Open Med (Poland)"},{"key":"2176_CR38","doi-asserted-by":"publisher","first-page":"703810","DOI":"10.3389\/fncel.2021.703810","volume":"15","author":"AJ Moulson","year":"2021","unstructured":"Moulson AJ, Squair JW, Franklin RJM, Tetzlaff W, Assinck P (2021) Diversity of reactive astrogliosis in CNS pathology: heterogeneity or plasticity? Front Cell Neurosci 15:703810. https:\/\/doi.org\/10.3389\/fncel.2021.703810","journal-title":"Front Cell Neurosci"},{"key":"2176_CR39","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s40035-021-00265-y","volume":"10","author":"C Wang","year":"2021","unstructured":"Wang C, Yang T, Liang M, Xie J, Song N (2021) Astrocyte dysfunction in Parkinson\u2019s disease: from the perspectives of transmitted \u03b1-synuclein and genetic modulation. Transl Neurodegener 10:1\u20137. https:\/\/doi.org\/10.1186\/s40035-021-00265-y","journal-title":"Transl Neurodegener"},{"key":"2176_CR40","doi-asserted-by":"publisher","first-page":"8618","DOI":"10.1523\/JNEUROSCI.0954-20.2020","volume":"40","author":"T Tsunemi","year":"2020","unstructured":"Tsunemi T, Ishiguro Y, Yoroisaka A, Valdez C, Miyamoto K, Ishikawa K, Saiki S, Akamatsu W, Hattori N, Krainc D (2020) Astrocytes protect human dopaminergic neurons from \u03b1-synuclein accumulation and propagation. J Neurosci 40:8618\u20138628. https:\/\/doi.org\/10.1523\/JNEUROSCI.0954-20.2020","journal-title":"J Neurosci"},{"key":"2176_CR41","doi-asserted-by":"publisher","first-page":"11835","DOI":"10.1523\/JNEUROSCI.0983-17.2017","volume":"37","author":"J Rostami","year":"2017","unstructured":"Rostami J, Holmqvist S, Lindstr\u00f6m V, Sigvardson J, Westermark GT, Ingelsson M, Bergstr\u00f6m J, Roybon L, Erlandsson A (2017) Human astrocytes transfer aggregated alpha-synuclein via tunneling nanotubes. J Neurosci 37:11835\u201311853. https:\/\/doi.org\/10.1523\/JNEUROSCI.0983-17.2017","journal-title":"J Neurosci"},{"key":"2176_CR42","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1016\/j.toxlet.2020.06.016","volume":"331","author":"Y Meng","year":"2020","unstructured":"Meng Y, Ding J, Li C, Fan H, He Y, Qiu P (2020) Transfer of pathological \u03b1-synuclein from neurons to astrocytes via exosomes causes inflammatory responses after METH exposure. Toxicol Lett 331:188\u2013199. https:\/\/doi.org\/10.1016\/j.toxlet.2020.06.016","journal-title":"Toxicol Lett"},{"key":"2176_CR43","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1186\/s40035-015-0042-0","volume":"4","author":"Q Wang","year":"2015","unstructured":"Wang Q, Liu Y, Zhou J (2015) Neuroinflammation in Parkinson\u2019s disease and its potential as therapeutic target. Transl Neurodegener 4:19. https:\/\/doi.org\/10.1186\/s40035-015-0042-0","journal-title":"Transl Neurodegener"},{"key":"2176_CR44","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1038\/s41591-018-0051-5","volume":"24","author":"SP Yun","year":"2018","unstructured":"Yun SP, Kam TI, Panicker N, Kim S, Oh Y, Park JS, Kwon SH, Park YJ, Karuppagounder SS, Park H, Kim S, Oh N, Kim NA, Lee S, Brahmachari S, Mao X, Lee JH, Kumar M, An D, Kang SU, Lee Y, Lee KC, Na DH, Kim D, Lee SH, Roschke VV, Liddelow SA, Mari Z, Barres BA, Dawson VL, Lee S, Dawson TM, Ko HS (2018) Block of A1 astrocyte conversion by microglia is neuroprotective in models of Parkinson\u2019s disease. Nat Med 24:931\u2013938. https:\/\/doi.org\/10.1038\/s41591-018-0051-5","journal-title":"Nat Med"},{"key":"2176_CR45","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1016\/j.neuron.2020.08.012","volume":"108","author":"M Linnerbauer","year":"2020","unstructured":"Linnerbauer M, Wheeler MA, Quintana FJ (2020) Astrocyte crosstalk in CNS inflammation. Neuron 108:608\u2013622. https:\/\/doi.org\/10.1016\/j.neuron.2020.08.012","journal-title":"Neuron"},{"key":"2176_CR46","doi-asserted-by":"publisher","first-page":"104647","DOI":"10.1016\/j.nbd.2019.104647","volume":"134","author":"E Aflaki","year":"2020","unstructured":"Aflaki E, Stubblefield BK, McGlinchey RP, McMahon B, Ory DS, Sidransky E (2020) A characterization of Gaucher iPS-derived astrocytes: Potential implications for Parkinson\u2019s disease. Neurobiol Dis 134:104647. https:\/\/doi.org\/10.1016\/j.nbd.2019.104647","journal-title":"Neurobiol Dis"},{"key":"2176_CR47","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1186\/s13024-018-0276-2","volume":"13","author":"C Kim","year":"2018","unstructured":"Kim C, Spencer B, Rockenstein E, Yamakado H, Mante M, Adame A, Fields JA, Masliah D, Iba M, Lee HJ, Rissman RA, Lee SJ, Masliah E (2018) Immunotherapy targeting toll-like receptor 2 alleviates neurodegeneration in models of synucleinopathy by modulating \u03b1-synuclein transmission and neuroinflammation. Mol Neurodegener 13:43. https:\/\/doi.org\/10.1186\/s13024-018-0276-2","journal-title":"Mol Neurodegener"},{"key":"2176_CR48","doi-asserted-by":"publisher","first-page":"14474","DOI":"10.1038\/s41598-020-71329-8","volume":"10","author":"TM Sonninen","year":"2020","unstructured":"Sonninen TM, H\u00e4m\u00e4l\u00e4inen RH, Koskuvi M, Oksanen M, Shakirzyanova A, Wojciechowski S, Puttonen K, Naumenko N, Goldsteins G, Laham-Karam N, Lehtonen M, Tavi P, Koistinaho J, Lehtonen \u0160 (2020) Metabolic alterations in Parkinson\u2019s disease astrocytes. Sci Rep 10:14474. https:\/\/doi.org\/10.1038\/s41598-020-71329-8","journal-title":"Sci Rep"},{"key":"2176_CR49","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1186\/s12868-015-0192-0","volume":"16","author":"EH Rannikko","year":"2015","unstructured":"Rannikko EH, Weber SS, Kahle PJ (2015) Exogenous \u03b1-synuclein induces toll-like receptor 4 dependent inflammatory responses in astrocytes. BMC Neurosci 16:57. https:\/\/doi.org\/10.1186\/s12868-015-0192-0","journal-title":"BMC Neurosci"},{"key":"2176_CR50","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1007\/s00401-018-1907-y","volume":"137","author":"CD Hughes","year":"2019","unstructured":"Hughes CD, Choi ML, Ryten M, Hopkins L, Drews A, Bot\u00eda JA, Iljina M, Rodrigues M, Gagliano SA, Gandhi S, Bryant C, Klenerman D (2019) Picomolar concentrations of oligomeric alpha-synuclein sensitizes TLR4 to play an initiating role in Parkinson\u2019s disease pathogenesis. Acta Neuropathol 137:103\u2013120. https:\/\/doi.org\/10.1007\/s00401-018-1907-y","journal-title":"Acta Neuropathol"},{"key":"2176_CR51","doi-asserted-by":"publisher","first-page":"109986","DOI":"10.1016\/J.INTIMP.2023.109986","volume":"117","author":"RM El-Sayed","year":"2023","unstructured":"El-Sayed RM, Abdelaziz AM, Zaki HF, Abdel NO, Rasheed (2023) Cilostazol novel neuroprotective mechanism against rotenone-induced Parkinson\u2019s disease in rats: Correlation between Nrf2 and HMGB1\/TLR4\/PI3K\/Akt\/mTOR signaling. Int Immunopharmacol 117:109986. https:\/\/doi.org\/10.1016\/J.INTIMP.2023.109986","journal-title":"Int Immunopharmacol"},{"key":"2176_CR52","doi-asserted-by":"publisher","first-page":"1174","DOI":"10.1124\/mol.118.112631","volume":"94","author":"KA Popichak","year":"2018","unstructured":"Popichak KA, Hammond SL, Moreno JA, Afzali MF, Backos DS, Slayden RD, Safe S, Tjalkens RB (2018) Compensatory expression of NuR77 and NURR1 regulates NF-KB\u2013dependent inflammatory signaling in astrocytes. Mol Pharmacol 94:1174\u20131186. https:\/\/doi.org\/10.1124\/mol.118.112631","journal-title":"Mol Pharmacol"},{"key":"2176_CR53","doi-asserted-by":"publisher","first-page":"114692","DOI":"10.1016\/J.INTIMP.2025.114692","volume":"156","author":"AM Abdelaziz","year":"2025","unstructured":"Abdelaziz AM (2025) Alpha-Synuclein drives NURR1 and NLRP3 Inflammasome dysregulation in Parkinson\u2019s disease: From pathogenesis to potential therapeutic strategies. Int Immunopharmacol 156:114692. https:\/\/doi.org\/10.1016\/J.INTIMP.2025.114692","journal-title":"Int Immunopharmacol"},{"key":"2176_CR54","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1186\/s12974-018-1302-6","volume":"15","author":"RH Du","year":"2018","unstructured":"Du RH, Zhou Y, Xia ML, Lu M, Ding JH (2018) Hu, \u03b1-Synuclein disrupts the anti-inflammatory role of Drd2 via interfering \u03b2-arrestin2-Table 1 interaction in astrocytes. J Neuroinflammation 15:258. https:\/\/doi.org\/10.1186\/s12974-018-1302-6","journal-title":"J Neuroinflammation"},{"key":"2176_CR55","doi-asserted-by":"publisher","first-page":"9248","DOI":"10.1523\/JNEUROSCI.1731-12.2012","volume":"32","author":"X Lin","year":"2012","unstructured":"Lin X, Parisiadou L, Sgobio C, Liu G, Yu J, Sun L, Shim H, Gu XL, Luo J, Long CX, Ding J, Mateo Y, Sullivan PH, Wu LG, Goldstein DS, Lovinger D, Cai H (2012) Conditional expression of Parkinson\u2019s disease-related mutant\u03b1-synuclein in the midbrain dopaminergic neurons causes progressive neurodegeneration and degradation of transcription factor nuclear receptor related 1. J Neurosci 32:9248\u20139264. https:\/\/doi.org\/10.1523\/JNEUROSCI.1731-12.2012","journal-title":"J Neurosci"},{"key":"2176_CR56","doi-asserted-by":"publisher","DOI":"10.1016\/J.INTIMP.2024.113839","author":"AM Abdelaziz","year":"2024","unstructured":"Abdelaziz AM, Rasheed NOA, Zaki HF, Salem HA, El-Sayed RM (2024) Canagliflozin attenuates neurodegeneration and ameliorates dyskinesia through targeting the NLRP3\/Nurr1\/GSK-3\u03b2\/SIRT3 pathway and autophagy modulation in rotenone-lesioned rats. Int Immunopharmacol. https:\/\/doi.org\/10.1016\/J.INTIMP.2024.113839","journal-title":"Int Immunopharmacol"},{"key":"2176_CR57","doi-asserted-by":"publisher","first-page":"8756","DOI":"10.1073\/pnas.1509742112","volume":"112","author":"CH Kim","year":"2015","unstructured":"Kim CH, Han BS, Moon J, Kim DJ, Shin J, Rajan S, Nguyen QT, Sohn M, Kim WG, Han M, Jeong I, Kim KS, Lee EH, Tu Y, Naffin-Olivos JL, Park CH, Ringe D, Yoon HS, Petsko GA, Kim KS (2015) Nuclear receptor Nurr1 agonists enhance its dual functions and improve behavioral deficits in an animal model of Parkinson\u2019s disease. Proc Natl Acad Sci U S A 112:8756\u20138761. https:\/\/doi.org\/10.1073\/pnas.1509742112","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2176_CR58","doi-asserted-by":"publisher","first-page":"E2517","DOI":"10.1073\/pnas.1502740112","volume":"112","author":"NM Urs","year":"2015","unstructured":"Urs NM, Bido S, Peterson SM, Daigle TL, Bass CE, Gainetdinov RR, Bezard E, Caron MG (2015) Targeting \u03b2-arrestin2 in the treatment of l-DOPA\u2013induced dyskinesia in Parkinson\u2019s disease. Proc Natl Acad Sci 112:E2517\u2013E2526","journal-title":"Proc Natl Acad Sci"},{"key":"2176_CR59","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1186\/s12974-020-01776-7","volume":"17","author":"J Rostami","year":"2020","unstructured":"Rostami J, Fotaki G, Sirois J, Mzezewa R, Bergstr\u00f6m J, Essand M, Healy L, Erlandsson A (2020) Astrocytes have the capacity to act as antigen-presenting cells in the Parkinson\u2019s disease brain. J Neuroinflammation 17:119. https:\/\/doi.org\/10.1186\/s12974-020-01776-7","journal-title":"J Neuroinflammation"},{"key":"2176_CR60","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1007\/s10863-019-09798-4","volume":"51","author":"LP Dolgacheva","year":"2019","unstructured":"Dolgacheva LP, Berezhnov AV, Fedotova EI, Zinchenko VP, Abramov AY (2019) Role of DJ-1 in the mechanism of pathogenesis of Parkinson\u2019s disease. J Bioenerg Biomembr 51:175\u2013188. https:\/\/doi.org\/10.1007\/s10863-019-09798-4","journal-title":"J Bioenerg Biomembr"},{"key":"2176_CR61","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1093\/brain\/awh054","volume":"127","author":"R Bandopadhyay","year":"2004","unstructured":"Bandopadhyay R, Kingsbury AE, Cookson MR, Reid AR, Evans IM, Hope AD, Pittman AM, Lashley T, Canet-Aviles R, Miller DW, McLendon C, Strand C, Leonard AJ, Abou-Sleiman PM, Healy DG, Ariga H, Wood NW, De Silva R, Revesz T, Hardy JA, Lees AJ (2004) The expression of DJ-1 (PARK7) in normal human CNS and idiopathic Parkinson\u2019s disease. Brain 127:420\u2013430. https:\/\/doi.org\/10.1093\/brain\/awh054","journal-title":"Brain"},{"key":"2176_CR62","doi-asserted-by":"publisher","first-page":"2478","DOI":"10.1096\/fj.08-125153","volume":"23","author":"J Waak","year":"2009","unstructured":"Waak J, Weber SS, Waldenmaier A, G\u00f6rner K, Alunni-Fabbroni M, Schell H, Vogt-Weisenhorn D, Pham TT, Reumers V, Baekelandt V, Wurst W, Kahle PJ (2009) Regulation of astrocyte inflammatory responses by the Parkinson\u2019s disease-associated gene DJ-1. FASEB J 23:2478\u20132489. https:\/\/doi.org\/10.1096\/fj.08-125153","journal-title":"FASEB J"},{"key":"2176_CR63","doi-asserted-by":"publisher","first-page":"2086","DOI":"10.1002\/glia.23828","volume":"68","author":"DJ Choi","year":"2020","unstructured":"Choi DJ, Yang H, Gaire S, Lee KA, An J, Kim BG, Jou I, Park SM, Joe EH (2020) Critical roles of astrocytic-CCL2-dependent monocyte infiltration in a DJ-1 knockout mouse model of delayed brain repair. Glia 68:2086\u20132101. https:\/\/doi.org\/10.1002\/glia.23828","journal-title":"Glia"},{"key":"2176_CR64","doi-asserted-by":"publisher","first-page":"156983","DOI":"10.1016\/J.CYTO.2025.156983","volume":"193","author":"SM Alshahrani","year":"2025","unstructured":"Alshahrani SM, Al-Kuraishy HM, Albuhadily AK, Al-Gareeb AI, Abdelaziz AM, Alexiou A, Papadakis M, Alruwaili M, Batiha GES (2025) GDF15 upregulation in Parkinson\u2019s disease: Compensatory mechanisms and causal insights. Cytokine 193:156983. https:\/\/doi.org\/10.1016\/J.CYTO.2025.156983","journal-title":"Cytokine"},{"key":"2176_CR65","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1007\/s00401-017-1746-2","volume":"134","author":"F Loria","year":"2017","unstructured":"Loria F, Vargas JY, Bousset L, Syan S, Salles A, Melki R, Zurzolo C (2017) \u03b1-Synuclein transfer between neurons and astrocytes indicates that astrocytes play a role in degradation rather than in spreading. Acta Neuropathol 134:789\u2013808. https:\/\/doi.org\/10.1007\/s00401-017-1746-2","journal-title":"Acta Neuropathol"},{"key":"2176_CR66","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/s40035-018-0143-7","volume":"8","author":"SZ Lu","year":"2019","unstructured":"Lu SZ, Guo YS, Liang PZ, Zhang SZ, Yin S, Yin YQ, Wang XM, Ding F, Gu XS, Zhou JW (2019) Suppression of astrocytic autophagy by \u03b1b-crystallin contributes to \u03b1-synuclein inclusion formation. Transl Neurodegener 8:3. https:\/\/doi.org\/10.1186\/s40035-018-0143-7","journal-title":"Transl Neurodegener"},{"key":"2176_CR67","doi-asserted-by":"publisher","first-page":"1686","DOI":"10.1016\/j.neurobiolaging.2015.01.015","volume":"36","author":"Y Liu","year":"2015","unstructured":"Liu Y, Zhou Q, Tang M, Fu N, Shao W, Zhang S, Yin Y, Zeng R, Wang X, Hu G, Zhou J (2015) Upregulation of alphaB-crystallin expression in the substantia nigra of patients with Parkinson\u2019s disease. Neurobiol Aging 36:1686\u20131691. https:\/\/doi.org\/10.1016\/j.neurobiolaging.2015.01.015","journal-title":"Neurobiol Aging"},{"key":"2176_CR68","doi-asserted-by":"publisher","first-page":"101039","DOI":"10.1016\/j.arr.2020.101039","volume":"59","author":"JL Gollihue","year":"2020","unstructured":"Gollihue JL, Norris CM (2020) Astrocyte mitochondria: Central players and potential therapeutic targets for neurodegenerative diseases and injury. Ageing Res Rev 59:101039. https:\/\/doi.org\/10.1016\/j.arr.2020.101039","journal-title":"Ageing Res Rev"},{"key":"2176_CR69","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1186\/s12974-017-1018-z","volume":"14","author":"G Gustafsson","year":"2017","unstructured":"Gustafsson G, Lindstr\u00f6m V, Rostami J, Nordstr\u00f6m E, Lannfelt L, Bergstr\u00f6m J, Ingelsson M, Erlandsson A (2017) Alpha-synuclein oligomer-selective antibodies reduce intracellular accumulation and mitochondrial impairment in alpha-synuclein exposed astrocytes. J Neuroinflammation 14:241. https:\/\/doi.org\/10.1186\/s12974-017-1018-z","journal-title":"J Neuroinflammation"},{"key":"2176_CR70","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1016\/j.mito.2018.12.002","volume":"47","author":"KZ Kuter","year":"2019","unstructured":"Kuter KZ, Olech \u0141, Dencher NA (2019) Increased energetic demand supported by mitochondrial electron transfer chain and astrocyte assistance is essential to maintain the compensatory ability of the dopaminergic neurons in an animal model of early Parkinson\u2019s disease. Mitochondrion 47:227\u2013237. https:\/\/doi.org\/10.1016\/j.mito.2018.12.002","journal-title":"Mitochondrion"},{"key":"2176_CR71","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1016\/j.bbi.2019.07.009","volume":"81","author":"ZL Hu","year":"2019","unstructured":"Hu ZL, Sun T, Lu M, Ding JH, Du RH, Hu G (2019) Kir6.1\/K-ATP channel on astrocytes protects against dopaminergic neurodegeneration in the MPTP mouse model of Parkinson\u2019s disease via promoting mitophagy. Brain Behav Immun 81:509\u2013522. https:\/\/doi.org\/10.1016\/j.bbi.2019.07.009","journal-title":"Brain Behav Immun"},{"key":"2176_CR72","doi-asserted-by":"publisher","first-page":"101284","DOI":"10.1016\/j.isci.2020.101284","volume":"23","author":"T Liang","year":"2020","unstructured":"Liang T, Qian ZM, Mu MD, Yung WH, Ke Y (2020) Brain hepcidin suppresses major pathologies in experimental Parkinsonism. IScience 23:101284. https:\/\/doi.org\/10.1016\/j.isci.2020.101284","journal-title":"IScience"},{"key":"2176_CR73","doi-asserted-by":"publisher","first-page":"455","DOI":"10.3389\/fnmol.2017.00455","volume":"10","author":"H Xu","year":"2018","unstructured":"Xu H, Wang Y, Song N, Wang J, Jiang H, Xie J (2018) New progress on the role of glia in iron metabolism and iron-induced degeneration of dopamine neurons in Parkinson\u2019s disease. Front Mol Neurosci 10:455. https:\/\/doi.org\/10.3389\/fnmol.2017.00455","journal-title":"Front Mol Neurosci"},{"key":"2176_CR74","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1016\/j.nurt.2010.07.001","volume":"7","author":"PM Rappold","year":"2010","unstructured":"Rappold PM, Tieu K (2010) Astrocytes and Therapeutics for Parkinson\u2019s Disease. Neurotherapeutics 7:413\u2013423. https:\/\/doi.org\/10.1016\/j.nurt.2010.07.001","journal-title":"Neurotherapeutics"},{"key":"2176_CR75","doi-asserted-by":"publisher","first-page":"1164","DOI":"10.1016\/S1474-4422(10)70254-4","volume":"9","author":"WJ Marks","year":"2010","unstructured":"Marks WJ, Bartus RT, Siffert J, Davis CS, Lozano A, Boulis N, Vitek J, Stacy M, Turner D, Verhagen L, Bakay R, Watts R, Guthrie B, Jankovic J, Simpson R, Tagliati M, Alterman R, Stern M, Baltuch G, Starr PA, Larson PS, Ostrem JL, Nutt J, Kieburtz K, Kordower JH, Olanow CW (2010) Gene delivery of AAV2-neurturin for Parkinson\u2019s disease: A double-blind, randomised, controlled trial. Lancet Neurol 9:1164\u20131172. https:\/\/doi.org\/10.1016\/S1474-4422(10)70254-4","journal-title":"Lancet Neurol"},{"key":"2176_CR76","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1002\/brb3.117","volume":"3","author":"S Back","year":"2013","unstructured":"Back S, Per\u00e4nen J, Galli E, Pulkkila P, Lonka-Nevalaita L, Tamminen T, Voutilainen MH, Raasmaja A, Saarma M, M\u00e4nnist\u00f6 PT, Tuominen RK (2013) Gene therapy with AAV2-CDNF provides functional benefits in a rat model of Parkinson\u2019s disease. Brain Behav 3:75\u201388. https:\/\/doi.org\/10.1002\/brb3.117","journal-title":"Brain Behav"},{"key":"2176_CR77","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1038\/nature21029","volume":"541","author":"SA Liddelow","year":"2017","unstructured":"Liddelow SA, Guttenplan KA, Clarke LE, Bennett FC, Bohlen CJ, Schirmer L, Bennett ML, M\u00fcnch AE, Chung WS, Peterson TC, Wilton DK, Frouin A, Napier BA, Panicker N, Kumar M, Buckwalter MS, Rowitch DH, Dawson VL, Dawson TM, Stevens B, Barres BA (2017) Neurotoxic reactive astrocytes are induced by activated microglia. Nature 541:481\u2013487. https:\/\/doi.org\/10.1038\/nature21029","journal-title":"Nature"},{"key":"2176_CR78","doi-asserted-by":"publisher","first-page":"e298","DOI":"10.1038\/emm.2016.159","volume":"49","author":"YC Chung","year":"2017","unstructured":"Chung YC, Baek JY, Kim SR, Ko HW, Bok E, Shin WH, Won SY, Jin BK (2017) Capsaicin prevents degeneration of dopamine neurons by inhibiting glial activation and oxidative stress in the MPTP model of Parkinson\u2019s disease. Exp Mol Med 49:e298. https:\/\/doi.org\/10.1038\/emm.2016.159","journal-title":"Exp Mol Med"},{"key":"2176_CR79","doi-asserted-by":"publisher","first-page":"5093493","DOI":"10.1155\/2020\/5093493","volume":"2020","author":"R Wi","year":"2020","unstructured":"Wi R, Chung YC, Jin BK (2020) Functional Crosstalk between CB and TRPV1 Receptors Protects Nigrostriatal Dopaminergic Neurons in the MPTP Model of Parkinson\u2019s Disease. J Immunol Res 2020:5093493. https:\/\/doi.org\/10.1155\/2020\/5093493","journal-title":"J Immunol Res"},{"key":"2176_CR80","doi-asserted-by":"publisher","first-page":"3431","DOI":"10.1007\/s11064-017-2388-4","volume":"42","author":"ZX Zhao","year":"2017","unstructured":"Zhao ZX, Wang JF, Wang LL, Yao XM, Liu YL, Li Y, Chen S, Yue T, Wang XT, Yu WF, Liu YM (2017) Capsaicin Protects Against Oxidative Insults and Alleviates Behavioral Deficits in Rats with 6-OHDA-Induced Parkinson\u2019s Disease via Activation of TRPV1. Neurochem Res 42:3431\u20133438. https:\/\/doi.org\/10.1007\/s11064-017-2388-4","journal-title":"Neurochem Res"},{"key":"2176_CR81","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1159\/000513678","volume":"28","author":"RW Du","year":"2021","unstructured":"Du RW, Bu WG (2021) Simvastatin Prevents Neurodegeneration in the MPTP Mouse Model of Parkinson\u2019s Disease via Inhibition of A1 Reactive Astrocytes. Neuroimmunomodulation 28:82\u201389. https:\/\/doi.org\/10.1159\/000513678","journal-title":"Neuroimmunomodulation"},{"key":"2176_CR82","doi-asserted-by":"publisher","first-page":"165","DOI":"10.3389\/fnmol.2018.00165","volume":"11","author":"H Tong","year":"2018","unstructured":"Tong H, Zhang X, Meng X, Lu L, Mai D, Qu S (2018) Simvastatin inhibits activation of nadph oxidase\/p38 MAPK pathway and enhances expression of antioxidant protein in parkinson disease models. Front Mol Neurosci 11:165. https:\/\/doi.org\/10.3389\/fnmol.2018.00165","journal-title":"Front Mol Neurosci"},{"key":"2176_CR83","doi-asserted-by":"publisher","DOI":"10.1002\/glia.22974","author":"N Yamamoto","year":"2016","unstructured":"Yamamoto N, Fujii Y, Kasahara R, Tanida M, Ohora K, Ono Y, Suzuki K, Sobue K (2016) Simvastatin and atorvastatin facilitates amyloid \u03b2-protein degradation in extracellular spaces by increasing neprilysin secretion from astrocytes through activation of MAPK\/Erk1\/2 pathways. Glia. https:\/\/doi.org\/10.1002\/glia.22974","journal-title":"Glia"},{"key":"2176_CR84","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.abg3198","author":"ZYD Wei","year":"2021","unstructured":"Wei ZYD, Shetty AK (2021) Treating Parkinson\u2019s disease by astrocyte reprogramming: progress and challenges. Sci Adv. https:\/\/doi.org\/10.1126\/sciadv.abg3198","journal-title":"Sci Adv"},{"key":"2176_CR85","doi-asserted-by":"publisher","DOI":"10.1016\/j.jare.2024.03.012","author":"YR Nam","year":"2024","unstructured":"Nam YR, Kang M, Kim M, Seok MJ, Yang Y, Han YE, Oh SJ, Kim DG, Son H, Chang MY, Lee SH (2024) Preparation of human astrocytes with potent therapeutic functions from human pluripotent stem cells using ventral midbrain patterning. J Adv Res. https:\/\/doi.org\/10.1016\/j.jare.2024.03.012","journal-title":"J Adv Res"},{"key":"2176_CR86","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1007\/s12031-008-9166-3","volume":"39","author":"M Bahat-Stroomza","year":"2009","unstructured":"Bahat-Stroomza M, Barhum Y, Levy YS, Karpov O, Bulvik S, Melamed E, Offen D (2009) Induction of adult human bone marrow mesenchymal stromal cells into functional astrocyte-like cells: Potential for restorative treatment in parkinson\u2019s disease. J Mol Neurosci 39:199\u2013210. https:\/\/doi.org\/10.1007\/s12031-008-9166-3","journal-title":"J Mol Neurosci"},{"key":"2176_CR87","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/J.NBD.2019.02.020","volume":"127","author":"KS Kirkley","year":"2019","unstructured":"Kirkley KS, Popichak KA, Hammond SL, Davies C, Hunt L, Tjalkens RB (2019) Genetic Suppression of IKK2\/NF-\u03baB in Astrocytes Inhibits Neuroinflammation and Reduces Neuronal Loss in the MPTP-Probenecid Model of Parkinson\u2019s Disease. Neurobiol Dis 127:193. https:\/\/doi.org\/10.1016\/J.NBD.2019.02.020","journal-title":"Neurobiol Dis"},{"key":"2176_CR88","doi-asserted-by":"publisher","first-page":"2739","DOI":"10.1007\/S00018-019-03111-7","volume":"76","author":"M Oksanen","year":"2019","unstructured":"Oksanen M, Lehtonen S, Jaronen M, Goldsteins G, H\u00e4m\u00e4l\u00e4inen RH, Koistinaho J (2019) Astrocyte alterations in neurodegenerative pathologies and their modeling in human induced pluripotent stem cell platforms. Cell Mol Life Sci 76:2739. https:\/\/doi.org\/10.1007\/S00018-019-03111-7","journal-title":"Cell Mol Life Sci"},{"key":"2176_CR89","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/S1474-4422(23)00378-2","volume":"23","author":"A McGarry","year":"2024","unstructured":"McGarry A, Rosanbalm S, Leinonen M, Olanow CW, To D, Bell A, Lee D, Chang J, Dubow J, Dhall R, Burdick D, Parashos S, Feuerstein J, Quinn J, Pahwa R, Afshari M, Ramirez-Zamora A, Chou K, Tarakad A, Luca C, Klos K, Bordelon Y, St Hiliare MH, Shprecher D, Lee S, Dawson TM, Roschke V, Kieburtz K (2024) Safety, tolerability, and efficacy of NLY01 in early untreated Parkinson\u2019s disease: a randomised, double-blind, placebo-controlled trial. Lancet Neurol 23:37\u201345. https:\/\/doi.org\/10.1016\/S1474-4422(23)00378-2","journal-title":"Lancet Neurol"},{"key":"2176_CR90","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/J.JPHS.2020.07.011","volume":"144","author":"L Iovino","year":"2020","unstructured":"Iovino L, Tremblay ME, Civiero L (2020) Glutamate-induced excitotoxicity in Parkinson\u2019s disease: The role of glial cells. J Pharmacol Sci 144:151\u2013164. https:\/\/doi.org\/10.1016\/J.JPHS.2020.07.011","journal-title":"J Pharmacol Sci"},{"key":"2176_CR91","doi-asserted-by":"publisher","first-page":"8941327","DOI":"10.1155\/2016\/8941327","volume":"2016","author":"Y Zhang","year":"2016","unstructured":"Zhang Y, Tan F, Xu P, Qu S (2016) Recent Advance in the Relationship between Excitatory Amino Acid Transporters and Parkinson\u2019s Disease. Neural Plast 2016:8941327. https:\/\/doi.org\/10.1155\/2016\/8941327","journal-title":"Neural Plast"},{"key":"2176_CR92","doi-asserted-by":"publisher","first-page":"184","DOI":"10.3390\/CELLS8020184","volume":"8","author":"S Mahmoud","year":"2019","unstructured":"Mahmoud S, Gharagozloo M, Simard C, Gris D (2019) Astrocytes Maintain Glutamate Homeostasis in the CNS by Controlling the Balance between Glutamate Uptake and Release. Cells 8:184. https:\/\/doi.org\/10.3390\/CELLS8020184","journal-title":"Cells"},{"key":"2176_CR93","doi-asserted-by":"publisher","first-page":"111349","DOI":"10.1016\/J.BRAINRESBULL.2025.111349","volume":"225","author":"NH Almohmadi","year":"2025","unstructured":"Almohmadi NH, Al-kuraishy HM, Al-Gareeb AI, Albuhadily AK, Abdelaziz AM, Jabir MS, Alexiou A, Papadakis M, Batiha GES (2025) Glutamatergic dysfunction in neurodegenerative diseases focusing on Parkinson\u2019s disease: Role of glutamate modulators. Brain Res Bull 225:111349. https:\/\/doi.org\/10.1016\/J.BRAINRESBULL.2025.111349","journal-title":"Brain Res Bull"},{"issue":"1","key":"2176_CR94","doi-asserted-by":"publisher","first-page":"71","DOI":"10.3390\/NEUROSCI5010005","volume":"5","author":"D Brash-Arias","year":"2024","unstructured":"Brash-Arias D, Garc\u00eda LI, P\u00e9rez-Estudillo CA, Rojas-Dur\u00e1n F, Aranda-Abreu GE, Herrera-Covarrubias D, Chi-Casta\u00f1eda D (2024) The role of astrocytes and alpha-synuclein in Parkinson\u2019s disease: a review. NeuroSci 5(1):71\u201386. https:\/\/doi.org\/10.3390\/NEUROSCI5010005","journal-title":"NeuroSci"},{"key":"2176_CR95","doi-asserted-by":"publisher","first-page":"17775","DOI":"10.1523\/JNEUROSCI.3049-12.2012","volume":"32","author":"L Gan","year":"2012","unstructured":"Gan L, Vargas MR, Johnson DA, Johnson JA (2012) Astrocyte-Specific Overexpression of Nrf2 Delays Motor Pathology and Synuclein Aggregation throughout the CNS in the Alpha-Synuclein Mutant (A53T) Mouse Model. J Neurosci 32:17775\u201317787. https:\/\/doi.org\/10.1523\/JNEUROSCI.3049-12.2012","journal-title":"J Neurosci"},{"issue":"3","key":"2176_CR96","doi-asserted-by":"publisher","first-page":"65","DOI":"10.3390\/ANTIOX6030065","volume":"6","author":"JR Liddell","year":"2017","unstructured":"Liddell JR (2017) Are astrocytes the predominant cell type for activation of Nrf2 in aging and neurodegeneration? Antioxidants 6(3):65. https:\/\/doi.org\/10.3390\/ANTIOX6030065","journal-title":"Antioxidants"},{"issue":"14","key":"2176_CR97","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41467-023-39038-8","volume":"14","author":"A de Rus Jacquet","year":"2023","unstructured":"de Rus Jacquet A, Alpaugh M, Denis HL, Tancredi JL, Boutin M, Decaestecker J, Beauparlant C, Herrmann L, Saint-Pierre M, Parent M, Droit A, Breton S, Cicchetti F (2023) The contribution of inflammatory astrocytes to BBB impairments in a brain-chip model of Parkinson\u2019s disease. Nat Commun 2023 14(14):1. https:\/\/doi.org\/10.1038\/s41467-023-39038-8","journal-title":"Nat Commun 2023"},{"key":"2176_CR98","doi-asserted-by":"publisher","first-page":"2454","DOI":"10.1172\/JCI60842","volume":"122","author":"AT Argaw","year":"2012","unstructured":"Argaw AT, Asp L, Zhang J, Navrazhina K, Pham T, Mariani JN, Mahase S, Dutta DJ, Seto J, Kramer EG, Ferrara N, Sofroniew MV, John GR (2012) Astrocyte-derived VEGF-A drives blood-brain barrier disruption in CNS inflammatory disease. J Clin Invest 122:2454\u20132468. https:\/\/doi.org\/10.1172\/JCI60842","journal-title":"J Clin Invest"},{"key":"2176_CR99","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1016\/J.NURT.2008.02.003","volume":"5","author":"AL Peterson","year":"2008","unstructured":"Peterson AL, Nutt JG (2008) Treatment of Parkinson\u2019s disease with trophic factors. Neurotherapeutics 5:270\u2013280. https:\/\/doi.org\/10.1016\/J.NURT.2008.02.003","journal-title":"Neurotherapeutics"},{"key":"2176_CR100","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1007\/S00441-020-03269-8","volume":"382","author":"DM Gash","year":"2020","unstructured":"Gash DM, Gerhardt GA, Bradley LH, Wagner R, Slevin JT (2020) GDNF clinical trials for Parkinson\u2019s disease: a critical human dimension. Cell Tissue Res 382:65\u201370. https:\/\/doi.org\/10.1007\/S00441-020-03269-8","journal-title":"Cell Tissue Res"},{"key":"2176_CR101","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1016\/J.STEM.2015.09.012","volume":"17","author":"L Zhang","year":"2015","unstructured":"Zhang L, Yin JC, Yeh H, Ma NX, Lee G, Chen XA, Wang Y, Lin L, Chen L, Jin P, Wu GY, Chen G (2015) Small molecules efficiently reprogram human astroglial cells into functional neurons. Cell Stem Cell 17:735. https:\/\/doi.org\/10.1016\/J.STEM.2015.09.012","journal-title":"Cell Stem Cell"},{"key":"2176_CR102","doi-asserted-by":"publisher","first-page":"8618","DOI":"10.1523\/JNEUROSCI.0954-20.2020","volume":"40","author":"T Tsunemi","year":"2020","unstructured":"Tsunemi T, Ishiguro Y, Yoroisaka A, Valdez C, Miyamoto K, Ishikawa K, Saiki S, Akamatsu W, Hattori N, Krainc D (2020) Astrocytes protect human dopaminergic neurons from \u03b1-synuclein accumulation and propagation. J Neurosci 40:8618\u20138628. https:\/\/doi.org\/10.1523\/JNEUROSCI.0954-20.2020","journal-title":"J Neurosci"},{"key":"2176_CR103","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.3233\/JPD-230284","volume":"13","author":"H Ozoran","year":"2023","unstructured":"Ozoran H, Srinivasan R (2023) Astrocytes and alpha-synuclein: friend or foe? J Parkinsons Dis 13:1289\u20131301. https:\/\/doi.org\/10.3233\/JPD-230284","journal-title":"J Parkinsons Dis"},{"key":"2176_CR104","doi-asserted-by":"publisher","first-page":"1241","DOI":"10.1097\/00004647-200411000-00008","volume":"24","author":"L Hertz","year":"2004","unstructured":"Hertz L (2004) The astrocyte-neuron lactate shuttle: a challenge of a challenge. J Cereb Blood Flow Metabolism 24:1241\u20131248. https:\/\/doi.org\/10.1097\/00004647-200411000-00008","journal-title":"J Cereb Blood Flow Metabolism"},{"key":"2176_CR105","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1016\/J.NEUROSCIENCE.2021.11.035","volume":"481","author":"K Yamagata","year":"2022","unstructured":"Yamagata K (2022) Lactate supply from astrocytes to neurons and its role in ischemic stroke-induced neurodegeneration. Neuroscience 481:219\u2013231. https:\/\/doi.org\/10.1016\/J.NEUROSCIENCE.2021.11.035","journal-title":"Neuroscience"},{"key":"2176_CR106","doi-asserted-by":"publisher","first-page":"2304","DOI":"10.1016\/J.NEUROBIOLAGING.2015.03.015","volume":"36","author":"T Jiang","year":"2015","unstructured":"Jiang T, Hoekstra J, Heng X, Kang W, Ding J, Liu J, Chen S, Zhang J (2015) P2X7 receptor is critical in \u03b1-synuclein-mediated microglial NADPH oxidase activation. Neurobiol Aging 36:2304\u20132318. https:\/\/doi.org\/10.1016\/J.NEUROBIOLAGING.2015.03.015","journal-title":"Neurobiol Aging"},{"key":"2176_CR107","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1111\/IMM.13264","volume":"162","author":"F Baidya","year":"2021","unstructured":"Baidya F, Bohra M, Datta A, Sarmah D, Shah B, Jagtap P, Raut S, Sarkar A, Singh U, Kalia K, Borah A, Wang X, Dave KR, Yavagal DR, Bhattacharya P (2021) Neuroimmune crosstalk and evolving pharmacotherapies in neurodegenerative diseases. Immunology 162:160\u2013178. https:\/\/doi.org\/10.1111\/IMM.13264","journal-title":"Immunology"},{"key":"2176_CR108","doi-asserted-by":"publisher","first-page":"105028","DOI":"10.1016\/j.nbd.2020.105028","volume":"144","author":"TI Kam","year":"2020","unstructured":"Kam TI, Hinkle JT, Dawson TM, Dawson VL (2020) Microglia and astrocyte dysfunction in parkinson\u2019s disease. Neurobiol Dis 144:105028. https:\/\/doi.org\/10.1016\/j.nbd.2020.105028","journal-title":"Neurobiol Dis"},{"key":"2176_CR109","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41531-021-00175-w","volume":"7","author":"P Ramos-Gonzalez","year":"2021","unstructured":"Ramos-Gonzalez P, Mato S, Chara JC, Verkhratsky A, Matute C, Cavaliere F (2021) Astrocytic atrophy as a pathological feature of Parkinson\u2019s disease with LRRK2 mutation. NPJ Parkinsons Dis 7:1\u201311. https:\/\/doi.org\/10.1038\/s41531-021-00175-w","journal-title":"NPJ Parkinsons Dis"},{"key":"2176_CR110","doi-asserted-by":"publisher","first-page":"105774","DOI":"10.1016\/j.neuint.2024.105774","volume":"178","author":"Z Cyske","year":"2024","unstructured":"Cyske Z, Gaffke L, Rintz E, Wi\u015bniewska K, W\u0119grzyn G, Pierzynowska K (2024) Molecular mechanisms of the ambroxol action in Gaucher disease and GBA1 mutation-associated Parkinson disease. Neurochem Int 178:105774. https:\/\/doi.org\/10.1016\/j.neuint.2024.105774","journal-title":"Neurochem Int"},{"key":"2176_CR111","doi-asserted-by":"publisher","first-page":"3119","DOI":"10.1007\/S12035-021-02327-8","volume":"58","author":"L Streubel-Gallasch","year":"2021","unstructured":"Streubel-Gallasch L, Giusti V, Sandre M, Tessari I, Plotegher N, Giusto E, Masato A, Iovino L, Battisti I, Arrigoni G, Shimshek D, Greggio E, Tremblay ME, Bubacco L, Erlandsson A, Civiero L (2021) Parkinson\u2019s disease\u2013associated LRRK2 interferes with astrocyte-mediated alpha-synuclein clearance. Mol Neurobiol 58:3119. https:\/\/doi.org\/10.1007\/S12035-021-02327-8","journal-title":"Mol Neurobiol"},{"key":"2176_CR112","doi-asserted-by":"publisher","first-page":"e12951","DOI":"10.1111\/TRA.12951","volume":"25","author":"H Liu","year":"2024","unstructured":"Liu H, Mao H, Ouyang X, Lu R, Li L (2024) Intercellular mitochondrial transfer: the novel therapeutic mechanism for diseases. Traffic 25:e12951. https:\/\/doi.org\/10.1111\/TRA.12951","journal-title":"Traffic"},{"key":"2176_CR113","doi-asserted-by":"publisher","first-page":"114268","DOI":"10.1016\/J.BIOPHA.2023.114268","volume":"159","author":"R Jain","year":"2023","unstructured":"Jain R, Begum N, Tryphena KP, Singh SB, Srivastava S, Rai SN, Vamanu E, Khatri DK (2023) Inter and intracellular mitochondrial transfer: Future of mitochondrial transplant therapy in Parkinson\u2019s disease. Biomed Pharmacother 159:114268. https:\/\/doi.org\/10.1016\/J.BIOPHA.2023.114268","journal-title":"Biomed Pharmacother"},{"key":"2176_CR114","doi-asserted-by":"publisher","first-page":"523399","DOI":"10.3389\/FNCEL.2020.00047\/BIBTEX","volume":"14","author":"J Cui","year":"2020","unstructured":"Cui J, Guo X, Li Q, Song N, Xie J (2020) Hepcidin-to-ferritin ratio is decreased in astrocytes with extracellular alpha-synuclein and iron exposure. Front Cell Neurosci 14:523399. https:\/\/doi.org\/10.3389\/FNCEL.2020.00047\/BIBTEX","journal-title":"Front Cell Neurosci"},{"key":"2176_CR115","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1016\/J.BBADIS.2018.01.008","volume":"1864","author":"N Song","year":"2018","unstructured":"Song N, Wang J, Jiang H, Xie J (2018) Astroglial and microglial contributions to iron metabolism disturbance in Parkinson\u2019s disease. Biochimica et Biophysica Acta (BBA) Mol Basis Disease 1864:967\u2013973. https:\/\/doi.org\/10.1016\/J.BBADIS.2018.01.008","journal-title":"Biochimica et Biophysica Acta (BBA) Mol Basis Disease"},{"key":"2176_CR116","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/J.TINS.2024.10.006","volume":"48","author":"LC Duret","year":"2025","unstructured":"Duret LC, Nagoshi E (2025) The intertwined relationship between circadian dysfunction and Parkinson\u2019s disease. Trends Neurosci 48:62\u201376. https:\/\/doi.org\/10.1016\/J.TINS.2024.10.006","journal-title":"Trends Neurosci"},{"key":"2176_CR117","doi-asserted-by":"publisher","first-page":"1464595","DOI":"10.3389\/FNCEL.2024.1464595","volume":"18","author":"K Xu","year":"2024","unstructured":"Xu K, Zhang Y, Shi Y, Zhang Y, Zhang C, Wang T, Lv P, Bai Y, Wang S (2024) Circadian rhythm disruption: a potential trigger in Parkinson\u2019s disease pathogenesis. Front Cell Neurosci 18:1464595. https:\/\/doi.org\/10.3389\/FNCEL.2024.1464595","journal-title":"Front Cell Neurosci"},{"key":"2176_CR118","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1046\/j.1471-4159.2003.02210.x","volume":"88","author":"T Dehmer","year":"2004","unstructured":"Dehmer T, Heneka MT, Sastre M, Dichgans J, Schulz JB (2004) Protection by pioglitazone in the MPTP model of Parkinson\u2019s disease correlates with I\u03baB\u03b1 induction and block of NF\u03baB and iNOS activation. J Neurochem 88:494\u2013501. https:\/\/doi.org\/10.1046\/j.1471-4159.2003.02210.x","journal-title":"J Neurochem"},{"key":"2176_CR119","doi-asserted-by":"publisher","first-page":"864140","DOI":"10.1155\/2008\/864140","volume":"2008","author":"A Bernardo","year":"2008","unstructured":"Bernardo A, Minghetti L (2008) Regulation of Glial Cell Functions by PPAR-\u03b3 Natural and Synthetic Agonists. PPAR Res 2008:864140. https:\/\/doi.org\/10.1155\/2008\/864140","journal-title":"PPAR Res"},{"key":"2176_CR120","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1002\/acn3.38","volume":"1","author":"E Yakunin","year":"2014","unstructured":"Yakunin E, Kisos H, Kulik W, Grigoletto J, Wanders RJA, Sharon R (2014) The regulation of catalase activity by PPAR \u03b3 is affected by \u03b1-synuclein. Ann Clin Transl Neurol 1:145\u2013159. https:\/\/doi.org\/10.1002\/acn3.38","journal-title":"Ann Clin Transl Neurol"},{"key":"2176_CR121","doi-asserted-by":"publisher","first-page":"3264","DOI":"10.3390\/ijms24043264","volume":"24","author":"I P\u00e9rez-Segura","year":"2023","unstructured":"P\u00e9rez-Segura I, Santiago-Balmaseda A, Rodr\u00edguez-Hern\u00e1ndez LD, Morales-Mart\u00ednez A, Mart\u00ednez-Becerril HA, Mart\u00ednez-G\u00f3mez PA, Delgado-Minjares KM, Salinas-Lara C, Mart\u00ednez-D\u00e1vila IA, Guerra-Crespo M, P\u00e9rez-Severiano F (2023) Soto-Rojas, PPARs and Their Neuroprotective Effects in Parkinson\u2019s Disease: A Novel Therapeutic Approach in \u03b1-Synucleinopathy? Int J Mol Sci 24:3264. https:\/\/doi.org\/10.3390\/ijms24043264","journal-title":"Int J Mol Sci"},{"key":"2176_CR122","doi-asserted-by":"publisher","first-page":"962","DOI":"10.1007\/s13311-021-01018-5","volume":"18","author":"LL Bu","year":"2021","unstructured":"Bu LL, Liu YQ, Shen Y, Fan Y, Yu WB, Jiang DL, Tang YL, Yang YJ, Wu P, Zuo CT, Koprich JB, Liu FT, Wu JJ, Wang J (2021) Neuroprotection of Exendin-4 by Enhanced Autophagy in a Parkinsonian Rat Model of \u03b1-Synucleinopathy. Neurotherapeutics 18:962. https:\/\/doi.org\/10.1007\/s13311-021-01018-5","journal-title":"Neurotherapeutics"},{"key":"2176_CR123","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/S1474-4422(23)00378-2","volume":"23","author":"A McGarry","year":"2024","unstructured":"McGarry A, Rosanbalm S, Leinonen M, Olanow CW, To D, Bell A, Lee D, Chang J, Dubow J, Dhall R, Burdick D, Parashos S, Feuerstein J, Quinn J, Pahwa R, Afshari M, Ramirez-Zamora A, Chou K, Tarakad A, Luca C, Klos K, Bordelon Y, St Hiliare MH, Shprecher D, Lee S, Dawson TM, Roschke V, Kieburtz K (2024) Safety, tolerability, and efficacy of NLY01 in early untreated Parkinson\u2019s disease: a randomised, double-blind, placebo-controlled trial. Lancet Neurol 23:37\u201345. https:\/\/doi.org\/10.1016\/S1474-4422(23)00378-2","journal-title":"Lancet Neurol"},{"key":"2176_CR124","doi-asserted-by":"publisher","DOI":"10.1002\/BRB3.2231","author":"MJ Lv","year":"2021","unstructured":"Lv MJ, Xue GF, Cheng HF, Meng PF, Lian X, H\u00f6lscher C, Li DF (2021) The GLP-1\/GIP dual-receptor agonist DA5-CH inhibits the NF-\u03baB inflammatory pathway in the MPTP mouse model of Parkinson\u2019s disease more effectively than the GLP-1 single-receptor agonist NLY01. Brain Behav. https:\/\/doi.org\/10.1002\/BRB3.2231","journal-title":"Brain Behav"},{"issue":"4","key":"2176_CR125","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1038\/cddis.2013.54","volume":"4","author":"K Kobayashi","year":"2013","unstructured":"Kobayashi K, Imagama S, Ohgomori T, Hirano K, Uchimura K, Sakamoto K, Hirakawa A, Takeuchi H, Suzumura A, Ishiguro N, Kadomatsu K (2013) Minocycline selectively inhibits M1 polarization of microglia. Cell Death Disease 2013 4(4):3. https:\/\/doi.org\/10.1038\/cddis.2013.54","journal-title":"Cell Death Disease 2013"},{"key":"2176_CR126","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.expneurol.2010.12.010","volume":"228","author":"AF Keller","year":"2011","unstructured":"Keller AF, Gravel M, Kriz J (2011) Treatment with minocycline after disease onset alters astrocyte reactivity and increases microgliosis in SOD1 mutant mice. Exp Neurol 228:69\u201379. https:\/\/doi.org\/10.1016\/j.expneurol.2010.12.010","journal-title":"Exp Neurol"},{"key":"2176_CR127","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1038\/jcbfm.2009.194","volume":"30","author":"M Tang","year":"2010","unstructured":"Tang M, Alexander H, Clark RSB, Kochanek PM, Kagan VE, Bayr H (2010) Minocycline reduces neuronal death and attenuates microglial response after pediatric asphyxial cardiac arrest. J Cereb Blood Flow Metab 30:119\u2013129. https:\/\/doi.org\/10.1038\/jcbfm.2009.194","journal-title":"J Cereb Blood Flow Metab"},{"key":"2176_CR128","doi-asserted-by":"publisher","first-page":"461337","DOI":"10.3389\/fphar.2019.00807","volume":"10","author":"S Grassi","year":"2019","unstructured":"Grassi S, Mauri L, Prioni S, Cabitta L, Sonnino S, Prinetti A, Giussani P (2019) Sphingosine 1-phosphate receptors and metabolic enzymes as druggable targets for brain diseases. Front Pharmacol 10:461337. https:\/\/doi.org\/10.3389\/fphar.2019.00807","journal-title":"Front Pharmacol"},{"key":"2176_CR129","doi-asserted-by":"publisher","first-page":"101618","DOI":"10.1016\/j.arr.2022.101618","volume":"78","author":"E Kip","year":"2022","unstructured":"Kip E, Parr-Brownlie LC (2022) Reducing neuroinflammation via therapeutic compounds and lifestyle to prevent or delay progression of Parkinson\u2019s disease. Ageing Res Rev 78:101618. https:\/\/doi.org\/10.1016\/j.arr.2022.101618","journal-title":"Ageing Res Rev"},{"issue":"1","key":"2176_CR130","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1038\/s41531-025-01117-6","volume":"11","author":"S An","year":"2025","unstructured":"An S, McInnis JJ, Kim D, Li Y, Tasdemir-Yilmaz O, Ahn J, Mackness BC, Kwon SH, Bonner JM, Yoo M, Dujardin S, Kim D, Park J, Yun H, Tang Y, Pradier L, Hyeon S, Song D, Sung B, Krishnan R, Spencer B, Rissman RA, Sandhu JK, Haqqani AS, Shin JW, Kim DB, Lee H, Jung J, You WK, Star AT, Delaney CE, Stanimirovic DB, Sardi SP, Lee SH, Kayatekin C (2025) A brain-shuttled antibody targeting alpha synuclein aggregates for the treatment of synucleinopathies. Npj Parkinson\u2019s Disease 11(1):254. https:\/\/doi.org\/10.1038\/s41531-025-01117-6","journal-title":"Npj Parkinson\u2019s Disease"},{"key":"2176_CR131","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1002\/mds.27562","volume":"34","author":"A Heras-Garvin","year":"2018","unstructured":"Heras-Garvin A, Weckbecker D, Ryazanov S, Leonov A, Griesinger C, Giese A, Wenning GK, Stefanova N (2018) Anle138b modulates \u03b1-synuclein oligomerization and prevents motor decline and neurodegeneration in a mouse model of multiple system atrophy. Mov Disord 34:255. https:\/\/doi.org\/10.1002\/mds.27562","journal-title":"Mov Disord"},{"key":"2176_CR132","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1007\/s00401-013-1114-9","volume":"125","author":"J Wagner","year":"2013","unstructured":"Wagner J, Ryazanov S, Leonov A, Levin J, Shi S, Schmidt F, Prix C, Pan-Montojo F, Bertsch U, Mitteregger-Kretzschmar G, Geissen M, Eiden M, Leidel F, Hirschberger T, Deeg AA, Krauth JJ, Zinth W, Tavan P, Pilger J, Zweckstetter M, Frank T, B\u00e4hr M, Weishaupt JH, Uhr M, Urlaub H, Teichmann U, Samwer M, B\u00f6tzel K, Groschup M, Kretzschmar H, Griesinger C, Giese A (2013) Anle138b: a novel oligomer modulator for disease-modifying therapy of neurodegenerative diseases such as prion and Parkinson\u2019s disease. Acta Neuropathol 125:795\u2013813. https:\/\/doi.org\/10.1007\/s00401-013-1114-9","journal-title":"Acta Neuropathol"},{"key":"2176_CR133","doi-asserted-by":"publisher","first-page":"463056","DOI":"10.3389\/fnins.2019.01028","volume":"13","author":"M Ramalingam","year":"2019","unstructured":"Ramalingam M, Huh YJ, Il Lee Y (2019) The impairments of \u03b1-Synuclein and mechanistic target of rapamycin in rotenone-induced SH-SY5Y cells and mice model of Parkinson\u2019s disease. Front Neurosci 13:463056. https:\/\/doi.org\/10.3389\/fnins.2019.01028","journal-title":"Front Neurosci"},{"key":"2176_CR134","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1089\/ars.2015.6549","volume":"25","author":"I Lastres-Becker","year":"2016","unstructured":"Lastres-Becker I, Garc\u00eda-Yag\u00fce AJ, Scannevin RH, Casarejos MJ, K\u00fcgler S, R\u00e1bano A, Cuadrado A (2016) Repurposing the NRF2 activator dimethyl fumarate as therapy against synucleinopathy in Parkinson\u2019s disease. Antioxid Redox Signal 25:61. https:\/\/doi.org\/10.1089\/ars.2015.6549","journal-title":"Antioxid Redox Signal"}],"container-title":["Inflammopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10787-026-02176-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10787-026-02176-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10787-026-02176-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T15:00:35Z","timestamp":1778857235000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10787-026-02176-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,27]]},"references-count":134,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["2176"],"URL":"https:\/\/doi.org\/10.1007\/s10787-026-02176-8","relation":{},"ISSN":["0925-4692","1568-5608"],"issn-type":[{"value":"0925-4692","type":"print"},{"value":"1568-5608","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,27]]},"assertion":[{"value":"20 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The authors declare they have no need of ethics approval and consent to participate as it is not applicable to this paper.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}